Breast Biopsy Devices

Breast Biopsy Devices

Global Breast Biopsy Devices Market to Reach US$2.5 Billion by 2030

The global market for Breast Biopsy Devices estimated at US$1.7 Billion in the year 2023, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$983.4 Million by the end of the analysis period. Growth in the Needle Based Biopsy Guns segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$454.4 Million While China is Forecast to Grow at 9.4% CAGR

The Breast Biopsy Devices market in the U.S. is estimated at US$454.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$551.7 Million by the year 2030 trailing a CAGR of 9.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Breast Biopsy Device Market - Key Trends and Drivers Summarized

Breast cancer remains a leading cause of cancer-related deaths among women worldwide. This underscores the critical need for effective screening tools that can accurately detect cancer early, improving patient outcomes and reducing mortality rates. Breast biopsy devices play a crucial role in diagnosing breast cancer and abnormalities, as accurate early detection can significantly reduce mortality rates. Market growth for these devices is driven by a rising incidence of breast cancer and advancements in imaging technology, such as mammography, MRI, and ultrasound. Image-guided biopsies now allow precise targeting of suspicious lesions, enhancing diagnostic accuracy while minimizing repeat procedures and patient discomfort. National screening programs have also increased awareness, leading to higher demand for biopsies.

Key trends include technological innovations such as vacuum-assisted biopsies and automated biopsy guns, which offer greater accuracy, less invasiveness, and improved patient comfort compared to traditional methods. Minimally invasive methods, such as vacuum-assisted needle biopsies, are gaining popularity due to reduced discomfort and scarring. Automated disposable biopsy devices help prevent infection, reduce operator fatigue, and increase efficiency. Integration with advanced imaging and AI technologies refines the biopsy process by identifying the best sites for tissue extraction, reducing unnecessary biopsies, and enhancing diagnostic efficiency.

Precision medicine is also shaping the biopsy market, as biomarker-driven insights from biopsy samples enable personalized treatment plans. AI helps tailor therapies based on individual genetic profiles and disease characteristics, providing clinicians with comprehensive analyses and actionable insights. This shift towards personalized and precision medicine is enhancing the biopsy`s value beyond diagnosis, leading to more effective and individualized cancer interventions.

Select Competitors (Total 23 Featured) -

• Aurora Imaging Technology, Inc.
• Becton, Dickinson and Company
• Becton, Dickinson and Company
• Hologic, Inc.
• Mammotome
• Planmed Oy

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.